|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Roche Holding AG, a leading manufacturer diagnostic and pharmaceutical products. |
|---|---|
| Transferring Party | NimbleGen Systems, Inc., a manufacturer of a proprietary suite of DNA microarrays, consumables, instruments and services. |
| Sector | Diagnostics |
| Date | June 19, 2007 |
| Analysis Roche gains entry into the market for high-density DNA microarrays (used in pharma research to understand genetic causes of disease and predisposition factors, comparative genomic analysis and identification of potential drug targets). Complements existing Roche portfolio of genomic research tools. NimbleGen has 140 employees in three facilities -- Wisconsin, Iceland and Germany. Deal value -- $272.5m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |